Cognetivity Neurosciences Stock Fundamentals
| CGNSF Stock | USD 0 0 42.86% |
Cognetivity Neurosciences fundamentals help investors to digest information that contributes to Cognetivity Neurosciences' financial success or failures. It also enables traders to predict the movement of Cognetivity Pink Sheet. The fundamental analysis module provides a way to measure Cognetivity Neurosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cognetivity Neurosciences pink sheet.
Cognetivity |
Cognetivity Neurosciences Company Shares Outstanding Analysis
Cognetivity Neurosciences' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cognetivity Neurosciences Shares Outstanding | 85.05 M |
Most of Cognetivity Neurosciences' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cognetivity Neurosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Cognetivity Neurosciences has 85.05 M of shares currently outstending. This is 52.89% lower than that of the Healthcare sector and significantly higher than that of the Health Information Services industry. The shares outstanding for all United States stocks is 85.13% higher than that of the company.
Cognetivity Neurosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cognetivity Neurosciences's current stock value. Our valuation model uses many indicators to compare Cognetivity Neurosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cognetivity Neurosciences competition to find correlations between indicators driving Cognetivity Neurosciences's intrinsic value. More Info.Cognetivity Neurosciences is number one stock in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cognetivity Neurosciences' earnings, one of the primary drivers of an investment's value.Cognetivity Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cognetivity Neurosciences' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Cognetivity Neurosciences could also be used in its relative valuation, which is a method of valuing Cognetivity Neurosciences by comparing valuation metrics of similar companies.Cognetivity Neurosciences is currently under evaluation in shares outstanding category among its peers.
Cognetivity Fundamentals
| Return On Equity | -6.43 | |||
| Return On Asset | -2.04 | |||
| Current Valuation | 15.68 M | |||
| Shares Outstanding | 85.05 M | |||
| Shares Owned By Insiders | 14.69 % | |||
| Price To Book | 189.01 X | |||
| Gross Profit | (4.02 M) | |||
| EBITDA | (13.04 M) | |||
| Net Income | (13.13 M) | |||
| Cash And Equivalents | 61.23 K | |||
| Total Debt | 1.37 M | |||
| Debt To Equity | 3.60 % | |||
| Current Ratio | 0.17 X | |||
| Book Value Per Share | (0.09) X | |||
| Cash Flow From Operations | (3.21 M) | |||
| Earnings Per Share | (0.14) X | |||
| Beta | 0.13 | |||
| Market Capitalization | 20.53 M | |||
| Total Asset | 2 M | |||
| Z Score | -11.4 | |||
| Net Asset | 2 M |
About Cognetivity Neurosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cognetivity Neurosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cognetivity Neurosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cognetivity Neurosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Cognetivity Neurosciences Ltd. operates as a healthcare company. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada. Cognetivity Neurosciences operates under Health Information Services classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Cognetivity Pink Sheet
Cognetivity Neurosciences financial ratios help investors to determine whether Cognetivity Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cognetivity with respect to the benefits of owning Cognetivity Neurosciences security.